Evidence map›Paper›PMID 34898327›Full record

ArticleTechnology in cancer research & treatment

3D Visualization of the Dynamic Bidirectional Talk Between ER/PR and Her2 Pathways.

Jiahong Lyv, Guohua Yu, Yunyun Zhang, Yan Lyv, Wenfeng Zhang, Jiandi Zhang, Fangrong Tang

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jiahong LyvYantai Quanticision Diagnostics, Inc, Yantai, P. R. China.
Guohua YuYuhuangding Hospital, affiliated Qingdao University, Yantai, P. R. China.ORCID 0000-0002-3260-3178
Yunyun ZhangYantai Quanticision Diagnostics, Inc, Yantai, P. R. China.
Yan LyvYantai Quanticision Diagnostics, Inc, Yantai, P. R. China.
Wenfeng ZhangYantai Quanticision Diagnostics, Inc, Yantai, P. R. China.
Jiandi ZhangYantai Quanticision Diagnostics, Inc, Yantai, P. R. China.ORCID 0000-0002-9282-9443
Fangrong TangYantai Quanticision Diagnostics, Inc, Yantai, P. R. China.
Qingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorMolecular ImagingSignal TransductionAdultAgedCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansImaging, Three-DimensionalImmunohistochemistryMaleMiddle AgedNeoplasm GradingNeoplasm StagingReceptors, EstrogenBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteronebiomarkerFFPEhigh throughputprotein quantitationQDB

Identifiers

PMID34898327
PMCPMC8674721
OpenAlexW4200114590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.